News Results for Shield Therapeutics (STX)
-
19 Oct
07:34Shield Therapeutics welcomes withdrawal by Teva of patent oppositionsIron deficiency focused Shield Therapeutics welcomed news that Teva Pharmaceutical Industries had withdrawn appeals regarding patent rulings. Shield said that Teva had withdrawn both its appeal...
-
16 Sep
12:05Stocks drift despite strong Hut Group IPO and M&A activityUK stocks erased their early gains to trade marginally lower on Wednesday as investors awaited an update from the Fed due later in the day regarding the outlook for the US economy. In contrast,...
-
16 Sep
07:46Shield Therapeutics swings to profit as revenue jumpsIron deficiency focused Shield Therapeutics swung to a first-half profit after it posted a large jump in revenue. Pre-tax profit for the six months through June amounted to £2.7m, compared to...
-
03 Jun
08:54Shield Therapeutics notes publication of supportive iron deficiency papersIron deficiency focused Shield Therapeutics noted that two scientific papers had been published concerning its lead product Feraccru. The European Respiratory Journal had published the results of...
-
26 May
08:02Shield Therapeutics appoints Hans Peter Hasler as chairmanIron deficiency focused Shield Therapeutics said it had appointed current director Hans Peter Hasler as its new chairman. Hasler had joined the company's board in July 2018 and was a previous...
-
01 May
16:56FTSE feels the manufacturing heat after poor data sees stocks close in the redUK markets fell sharply during the Friday session following a weak opening on Wall Street as ups the ante in his pandemic spate with China. The US President claims to have seen evidence that the...
-
01 May
12:34FTSE plunges as UK manufacturing shows sharpest drop on record; Ryanair to slash 3,000 jobsUK markets fell sharply into the weekend after dismal UK manufacturing data added to the gloomy economic numbers from the US and across Europe yesterday. At midday, the benchmark FTSE 100 index...
-
01 May
08:31UK stocks open 2.4% lower as earnings pessimism takes holdUK stocks opened substantially lower on Friday after Apple and Amazon provided disappointing earnings updates and budget carrier Ryanair warned of a long-lingering impact from the Covid-19 crisis....
-
01 May
07:42Shield Therapeutics forecasts fall in revenue after disappointing trial resultIron deficiency focused Shield Therapeutics said it had seen minimal disruption commercially from the Covid-19 crisis, though it warned of a fall in revenue due to a disappointing trial result....
-
22 Apr
08:58Shield Therapeutics CEO and founder Carl Sterritt resigns with immediate effectIron deficiency focused Shield Therapeutics said founder and chief executive Carl Sterritt had resigned with immediate effect. Sterritt had left 'following discussions with major shareholders and...
-
17 Mar
09:17Shield Therapeutics launches independent review after 'clarifying' trial resultsIron deficiency focused Shield Therapeutics said it had initiated an independent review of a clinical trial after it was forced to clarify the results. The company conceded that an announcement it...
-
27 Jan
07:35Shield Therapeutics sees revenue falling as expectedIron deficiency focused Shield Therapeutics said it expected to post a fall in revenue that was nevertheless in line with market expectations. Revenue for the year through December was seen...
-
08 Jan
09:37Shield Therapeutics secures China licence agreement for lead product for $11.4mPharmaceutical company Shield Therapeutics has secured a licence agreement in China for its lead product Feraccru/Accrufer. The deal is an exclusive licence agreement with Beijing Aosaikang...
-
22 Oct
09:40Shield Therapeutics to present positive study data at Hamburg eventShield Therapeutics said it would present positive study results for its iron deficiency treatment at in Hamburg on Tuesday. The presentation would be held as part of United European...
-
15 Aug
11:40Director Deals - Shield Therapeutics Plc (STX)James Karis, Chairman, bought 75,000 shares in the company on the 13th August 2019 at a price of 178.00p. The Director now holds 161,667 shares representing 0.00% of the shares in issue. Story...
-
07 Aug
08:13Shield Therapeutics losses narrow as sales rise, R&D spending fallsIron deficiency focused Shield Therapeutics booked a narrower first-half loss, as its grew sales and lowered spending on research and development. Pre-tax losses for the six months through June...
-
26 Jul
09:30Broker Forecast - Peel Hunt issues a broker note on Shield Therapeutics PlcPeel Hunt today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 200p (from 88p). Story provided by StockMarketWire.com Broker Forecasts...
-
26 Jul
08:36Shield Therapeutics wins FDA approval for anaemia drugPharmaceutical company Shield Therapeutics said it had received FDA approval in the United States for its Feraccru (Accrufer in the US) drug for the treatment of iron deficiency in adults. The...
-
03 Jun
08:51UK stocks open 1.1% lower as trade tensions escalateUK stocks opened substantially lower on Monday after oil and mining stocks were hurt by growing fears about the health of US trade relationships with China and Mexico. At 0848, the FTSE 100 was...
-
03 Jun
07:50Shield Therapeutic says Teva Pharmaceutical has filed appeal over patent rulingIron deficiency focused Shield Therapeutics said that Teva Pharmaceutical Industries had filed a notice of appeal regarding a previous patent ruling. Teva had filed a notice of appeal to the...
-
14 May
08:40Broker Forecast - finnCap issues a broker note on Shield Therapeutics PlcfinnCap today initiates coverage of Shield Therapeutics Plc (LON:STX) with a corporate investment rating and price target of 200p. Story provided by StockMarketWire.com Broker Forecasts data...
-
24 Apr
07:10Shield Therapeutics iron deficiency treatment gets Swiss regulatory nodShield Therapeutics said Swiss regulators had extended the approved indication for its iron deficiency treatment to now include treatment of all adults with iron deficiency with or without...
-
17 Apr
17:40Director Deals - Shield Therapeutics Plc (STX)Carl Sterritt, Chief Executive Officer, exercised 123,690 shares in the company on the 16th April 2019 at a price of 1.50p. The Director now holds 10,198,951 shares. Story provided by...
-
12 Mar
09:30Broker Forecast - Peel Hunt issues a broker note on Shield Therapeutics PlcPeel Hunt today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 88p (from 70p). Story provided by StockMarketWire.com Broker Forecasts data...
-
04 Mar
08:16Shield Therapeutics records positive results from trial of iron deficiency treatmentShield Therapeutics said it had recorded positive results from a clinical trial of its iron replacement therapy Feraccru. The AEGIS-H2H clinical trial compared Feraccru to Ferinject, or FCM, the...
-
19 Feb
08:00Broker Forecast - Liberum Capital issues a broker note on Shield Therapeutics PlcLiberum Capital today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 116p (from 80p). Story provided by StockMarketWire.com Broker...
-
29 Jan
08:07Shield Therapeutics reports promising results from iron-deficiency treatment studyShield Therapeutics reported positive results from a further study of a treatment for iron deficiency in adults with inflammatory bowel disease. The open-label extension phase of the study of...
-
22 Jan
07:37Shield Therapeutics appoints James Karis as chairmanIron deficiency focused Shield Therapeutics said it had appointed James Karis as its new chairman with immediate effect. Karis had served on the company's board for almost three years and had...
-
05 Dec
13:10Shield Therapeutics partner starts selling iron deficiency treatment UKShield Therapeutics said that European distribution partner Norgine had launched its iron deficiency treatment in the UK. Sheild in September licensed the so-called Feraccru treatment to Norgine...
-
03 Dec
07:15Shield Therapeutics iron deficiency treatment accepted by FDA for reviewShield Therapeutics said the US Food and Drug Administration had accepted for review a new drug application for its lead iron deficiency product. The regulator would shortly confirm to Shield the...
-
01 Oct
07:17Shield Therapeutics gets FDA confirmation for drug applicationShield Therapeutics said it received confirmation from the US Federal Drug Administration of a successful submission of a new drug application for iron deficiency treatment Feraccru. The product...
-
24 Sep
15:00Director Deals - Shield Therapeutics Plc (STX)Carl Sterritt, Chief Executive Officer, bought 88,235 shares in the company on the 21st September 2018 at a price of 34.00p. The Director now holds 10,163,496 shares. Story provided by...
-
24 Sep
08:20Broker Forecast - Peel Hunt issues a broker note on Shield Therapeutics PlcPeel Hunt today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and set its price target at 70p. Story provided by StockMarketWire.com Broker Forecasts data provided by...
-
20 Sep
08:40Broker Forecast - Liberum Capital issues a broker note on Shield Therapeutics PlcLiberum Capital today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and set its price target at 80p. Story provided by StockMarketWire.com Broker Forecasts data...
-
19 Sep
07:52Shield Therapeutics posts loss; inks sales pact with NorgineShield Therapeutics posted a first-half loss as it continued to invest in bringing its iron deficiency treatments towards commercialisation. The company also announced that it had entered into an...
-
23 Jul
08:12Shield Therapeutics says iron deficiency treatment sales rise in Germany, UKShield Therapeutics said its revenue in the first half was expected to reach £0.5m, following increased sales of its Feraccru iron deficiency treatment in Europe. The company's shares plunged in...
-
05 Jun
09:53Shield Therapeutics chairman Andrew Heat standing downShield Therapeutics said Andrew Heath would stand down as chairman to focus on other business interests. A process to appoint a successor to Heath, who became chairman in early 2016, was underway,...
-
11 Apr
09:49Shield Therapeutics losses deepen, to cut headcount and promotional spendingShield Therapeutics said annual losses deepened and that it would cut jobs and promotional spending to conserve cash, amid headwinds proving up the effectiveness of its Feraccru iron deficiency...
-
06 Apr
09:03UK stocks open 0.2% lower as trade war fears persistUK stocks opened lower on Friday as persistent trade-war fears continued to unsettle global markets. At 0856, the benchmark FTSE 100 index was down 15.23 points, or 0.2%, at 7.184,27 on what was a...
-
06 Apr
07:15Shield Therapeutics to re-submit US drug application without more trialsShield Therapeutics said minutes from a US Food and Drug Administration meeting regarding its iron deficiency treatment Feraccru indicated it could re-submit a new drug application without...
-
27 Mar
09:28Shield Therapeutics gets extended European approval for iron-deficiency treatmentShield Therapeutics said the European Commission had decided to extend the approved indication for its Feraccru product to include treatment of all adults with iron deficiency, with or without...
-
16 Mar
07:48Shield Therapeutics awaits FDA opinion on alteration to clinical study resultsShield Therapeutics said it altered the results of a clinical study on a treatment for iron deficiency in a fashion that may, or may not, be accepted by the US Federal Drug Administration. A small...
-
23 Feb
14:18Shield Therapeutics gets European nod for iron deficiency treatmentShield Therapeutics said European regulators had recommended marketing authorisation approval of its Feraccru treatment be extended to include all adults with iron deficiency, with or without...
-
22 Feb
09:23Shield Therapeutics cuts costs ahead of Feraccru decisionShield Therapeutics, a commercial stage, pharmaceutical company, is cutting costs ahead of a decision on the future of Feraccru - its lead asset which is approved and marketed in Europe for the...
-
05 Feb
16:45FTSE remains weak on rate concerns but US steadiesThe UK and Europe were in the red as concerns over potential rises in interest rates this year soured the market. The FTSE 100 was 1.4% lower at 7,334. However fears of a more significant...
-
05 Feb
11:49FTSE hit by global sell-offThe global sell-off continued in the US last week and Asia today on the back of rising government bond yields and an expected hike in interest rates. The negative sentiment spread to the UK's FTSE...
-
05 Feb
09:42Shield Therapeutics clinical trial fails to meet objectivesShield Therapeutics said a clinical trial of its Feraccru treatment for anemia failed to meet the study's primary objectives. 'We are surprised and disappointed by these top-line findings,' chief...
-
10 Oct
08:10Shield Therapeutics readies drug studyShield Therapeutics said it has finished enrolling subjects for the Phase 3 AEGIS-CKD study of its European-marketed product, Feraccru. Top-line data, based on a 16-week primary endpoint, is...
-
05 Oct
09:00Director Deals - Shield Therapeutics Plc (STX)Carl Sterritt, Chief Executive Officer, bought 8,814 shares in the company on the 4th October 2017 at a price of 100.00p. The Director now holds 10,075,261 shares. NOTE: Call option Story...
-
22 Sep
11:00Broker Forecast - finnCap issues a broker note on Shield Therapeutics PlcfinnCap today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and cut its price target to 265p (from 270p). Story provided by StockMarketWire.com
-
07 Sep
08:10Broker Forecast - finnCap issues a broker note on Shield Therapeutics PlcfinnCap today initiates coverage of Shield Therapeutics Plc (LON:STX) with a buy investment rating and price target of 270p. Story provided by StockMarketWire.com
-
06 Sep
07:40Shield announces USPTO approval of 'composition of matter patent' for FeraccruShield Therapeutics announced that the United States Patent and Trademark Office (USPTO) allowed a composition of matter patent protecting the active substance of Feraccru, the group's lead...
-
15 Jun
14:15Shield Therapeutics raises £12mShield Therapeutics has announced that the Company has raised approximately £12m (before expenses) through: - a co-ordinated exercise of 6,870,536 existing warrants at an exercise price of 150p...
-
15 Jun
10:01Shield Therapeutics plans to raise c.£12mShield Therapeutics plans to raise a total of about £12m gross at 150p a share. This would be achieved via a warrant exercise to raise about 10.3m, a placing to raise about £1.5m and a subscription...
-
04 Apr
10:30Broker Forecast - Liberum Capital issues a broker note on Shield Therapeutics PlcLiberum Capital today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and cut its price target to 245p (from 310p). Story provided by StockMarketWire.com
-
04 Apr
07:15FLASH: Shield Therapeutics narrows FY pretax lossStory provided by StockMarketWire.com
-
04 Apr
07:05FLASH: Shield Therapeutics appoints Chief Financial OfficerStory provided by StockMarketWire.com
-
06 Jan
11:28Shield Therapeutics P&R agreements slower than expectedShield Therapeutics reported that pricing and reimbursement (P&R) agreements were slower than expected for its oral iron product Feraccru, although these approvals are now coming through. The...
-
20 Sep
14:10Broker Forecast - Canaccord Genuity issues a broker note on Shield Therapeutics PlcCanaccord Genuity today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 241p (from 235p). Story provided by StockMarketWire.com
-
15 Aug
16:24Shield schedules interimsShield Therapeutics, a speciality pharmaceutical company focused on secondary care, will report its results for the six months ended 30 June on 20 September. At 4:24pm: (LON:STX) Shield...
-
18 Jul
12:10Broker Forecast - Canaccord Genuity issues a broker note on Shield Therapeutics PlcCanaccord Genuity today initiates coverage of Shield Therapeutics Plc (LON:STX) with a buy investment rating and price target of 235p. Story provided by StockMarketWire.com
-
14 Jun
07:08FLASH: Shield Therapeutics posts FY pretax lossStory provided by StockMarketWire.com
-
23 Mar
13:18Shield Therapeutics schedules FY resultsShield Therapeutics has changed its accounting reference date from 30 September to 31 December and will publish its results for the year to the end of December 2015 on 14 June. At 1:18pm:...
-
26 Feb
13:29Shield Therapeutics trading on AIMShield Therapeutics, a speciality pharmaceutical company focused on secondary care, started trading on AIM today with a market capitalisation of approximately GBP162 million. At 1:29pm:...
-
26 Feb
07:45Shield Therapeutics says Feraccru gets EU approvalShield Therapeutics said the European Commission has granted marketing authorisation across all member states for its wholly owned product, Feraccru, as a treatment for adults with iron deficiency...
-
26 Feb
07:14FLASH: Shield Therapeutics says Feraccru gets EU approvalStory provided by StockMarketWire.com
-
12 Feb
11:28Shield Therapeutics raises GBP32.5m for AIM debutShield Therapeutics has raised gross proceeds of GBP32.5m via a placing and subscription of shares and the issue of warrants to subscribe for shares to a group of institutional, existing and other...